GlassScriptPhysician profile
Aalok Sahai
NPI 1235343278
$2,018.74
in general payments reported to CMS, 2019-2025
22 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $146 · 2021: $216 · 2022: $75.83 · 2023: $176 · 2024: $790 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053 · Travel and Lodging: $204 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.56 |
| Travel and Lodging | $204.17 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,160.02 | 2019-2025 | |
| Smith+Nephew, INC. | $297.26 | 2021-2025 | Stravix Pl, Renasys Touch, Pico |
| Coloplast Corp | $105.63 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $56.97 | 2019-2022 | |
| Abbott Laboratories | $50.68 | 2021 | |
| Ethicon US, LLC | $46.94 | 2019-2024 | Echelon; Endopath |
| Baxter Healthcare | $32.57 | 2023-2024 | Seprafilm, Perclot |
| Medtronic, INC. | $30.30 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.33 | 2020 | |
| Covidien LP | $27.90 | 2019-2020 | |
| Boston Scientific Corporation | $23.66 | 2025 | Axonics |
| Myriad Genetic Laboratories, INC. | $18.33 | 2025 | Myrisk |
| Depuy Synthes Sales INC. | $16.75 | 2023 | Monovisc, Orthovisc |
| Tela Bio, INC. | $16.35 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Pacira Pharmaceuticals Incorporated | $15.59 | 2024 | Exparel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $15.37 | 2025 | |
| Averitas Pharma INC. | $15.11 | 2024 | Qutenza |
| Daiichi Sankyo INC. | $14.11 | 2019 | |
| Innovation Technologies INC | $13.39 | 2024 | Irrisept |
| Olympus America INC. | $12.45 | 2021 | |
| Braintree Laboratories, INC. | $11.32 | 2021 | |
| Acacia Pharma INC | $8.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aalok Sahai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.